Pharmacopeia

CWP-0213

Prednisone

Endocrine · Level 3

Core pharmacology

Class Group

Systemic synthetic glucocorticoid; orally administered prodrug of prednisolone.

Main Action

Anti-inflammatory, immunosuppressive and metabolic glucocorticoid effects.

Mechanism of action

After hepatic conversion to prednisolone, binds cytoplasmic glucocorticoid receptors and alters transcription of anti-inflammatory and pro-inflammatory genes; reduces cytokine-mediated inflammation and immune-cell activation.

Indications Uses

Wide range of steroid-responsive inflammatory, autoimmune, allergic and other disorders; selection and dosing depend on condition. Not equivalent to mineralocorticoid-rich hydrocortisone.

Absorption

Readily absorbed after oral administration; prednisolone is the active circulating metabolite.

Distribution

Active prednisolone is highly protein bound (about 90–95% at usual concentrations); crosses placenta and reaches breast milk.

Metabolism

Hepatic 11-beta-hydroxysteroid dehydrogenase converts prednisone to active prednisolone; prednisolone subsequently undergoes hepatic conjugation.

Excretion

Prednisolone and its conjugated metabolites are eliminated in urine; relatively little prednisone is excreted unchanged.

Half-life

Reported prednisone plasma half-life approximately 3–4 hours after oral dosing; biological anti-inflammatory effects last longer than the plasma half-life.

Adverse Effects Toxicity

Hyperglycaemia, infection risk, psychiatric disturbance, myopathy, fluid/blood-pressure effects, osteoporosis and hypothalamic-pituitary-adrenal suppression (especially with prolonged courses).

Special Points

Prednisone requires hepatic conversion to prednisolone; consider direct prednisolone in significant hepatic dysfunction where impaired activation is a concern. Tapering depends on duration/dose and risk of adrenal suppression; avoid abrupt withdrawal after sustained treatment.

Source references

These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.